Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
about
Ceftobiprole for the treatment of pneumonia: a European perspectiveCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaCeftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Emerging agents to combat complicated and resistant infections: focus on ceftobiproleSynergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbitsCeftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Emerging drugs in sepsis.Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.Novel antibiotics for the treatment of Staphylococcus aureus.Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.A Highly Potent Class of Halogenated Phenazine Antibacterial and Biofilm-Eradicating Agents Accessed Through a Modular Wohl-Aue Synthesis.Daptomycin versus Vancomycin in an Enterococcus faecalis Endophthalmitis Rabbit Model.Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.
P2860
Q26796463-F843818D-8700-418F-94A7-B3F0D9F3575BQ28085517-E7C8E9CC-9D50-44CD-8DFA-A16011757589Q34417616-1566F104-0A3E-49E3-9EB6-0C8128FFA431Q34433342-BA20B359-6A70-43DB-B480-AB96FBF21AB6Q35026567-3CF58A45-4E13-4C37-B9A6-571A571ECAA9Q35806369-CF302FAA-0C6C-4976-B641-0B48C1CA13BFQ36396146-D362A321-8BA5-4FC8-835B-279707E6943AQ37461413-A390CE9B-60BB-4615-8BE0-15AF0483052FQ37593094-2B7C65FD-D876-4D8D-B507-3491990F7B65Q37670186-5C3CE996-4819-4CF4-B9CF-F4902ED52647Q37752231-F5688557-7537-43C8-B2ED-55A282047913Q37785546-5E80EA2E-9E30-4BD2-BE75-2174D1A9558AQ38099393-EE077541-075F-4AFB-B793-44FC892F87DFQ39164183-92833F19-7A5F-42E0-9ECA-1F6B21094404Q39933945-58A23067-37B7-41D1-B267-C1646315AAAAQ40003834-B955147E-B2CC-442B-A2F1-466042AA8AEEQ40208622-8CA26C1C-D0C8-44AB-A236-70D5F07BA2BEQ41498849-130C614A-C421-433A-9AA6-8B72CDD093E1Q43065479-66E654FB-E467-49BF-B2EC-C0DDE63BE3CDQ46178941-CB323610-FCBD-429B-8026-B3ACB269CD0F
P2860
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Activities of ceftobiprole, li ...... sistant Staphylococcus aureus.
@en
type
label
Activities of ceftobiprole, li ...... sistant Staphylococcus aureus.
@en
prefLabel
Activities of ceftobiprole, li ...... sistant Staphylococcus aureus.
@en
P2093
P2860
P356
P1476
Activities of ceftobiprole, li ...... sistant Staphylococcus aureus.
@en
P2093
Chrissy M Cheung
Michael J Rybak
Steven N Leonard
P2860
P304
P356
10.1128/AAC.00257-08
P407
P577
2008-06-02T00:00:00Z